Melanotan II

Melanotan II (MT-II) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone developed at the University of Arizona in the 1980s. It works by non-selectively activating melanocortin receptors MC1R, MC3R, MC4R, and MC5R throughout the body. MC1R activation stimulates melanin production in skin cells, producing a tanning effect. MC4R activation in the brain produces sexual arousal and appetite suppression. This non-selectivity is why MT-II produces multiple effects simultaneously — tanning, sexual function changes, and appetite changes — rather than targeting one pathway.

The evidence is inconclusive but concerning. A 2017 review (PMID: 28266027) documented four cases of melanoma emerging from existing moles during or after MT-II use, and a case report described melanoma in a 20-year-old user (PMID: 24355990). Some analyses suggest increased UV-seeking behavior among users may partly explain the association. However, a 2025 case report documented oral mucosal melanoma in a young MT-II nasal spray user — oral mucosa is not UV-exposed tissue, suggesting direct melanocyte overstimulation may independently contribute to risk. Both UV behavior and direct melanocyte stimulation are plausible mechanisms. No long-term safety studies exist. Individuals with many moles, dysplastic nevi, or family history of melanoma should avoid MT-II.

The most common side effects are nausea (up to 12.9% at higher doses), facial flushing, and in men, spontaneous erections occurring 1-5 hours after injection. Other common effects include headache, decreased appetite, fatigue, and yawning. Dermatological effects include darkening of existing moles, formation of new moles, and freckle intensification. These side effects are typically most pronounced during the loading phase and tend to diminish with continued use. Starting at lower doses (100-250 mcg) and injecting before bedtime are common strategies to manage initial nausea.

PT-141 was developed directly from MT-II research. The key difference is receptor selectivity: MT-II activates MC1R, MC3R, MC4R, and MC5R (producing tanning, sexual effects, and appetite changes), while PT-141 selectively targets MC3R and MC4R only (sexual function without tanning). PT-141 received FDA approval in 2019 as Vyleesi for female hypoactive sexual desire disorder. MT-II remains unapproved. PT-141 has a shorter half-life of approximately 2 hours. For someone seeking only sexual function enhancement, PT-141 offers a targeted option; for someone seeking tanning plus sexual effects, MT-II activates both pathways simultaneously.

Melanotan I (afamelanotide) is a linear 13-amino-acid alpha-MSH analog that selectively targets MC1R for skin pigmentation only. Melanotan II is a shorter cyclic peptide that non-selectively activates MC1R, MC3R, MC4R, and MC5R. Result: MT-I produces pigmentation without sexual side effects, nausea, or appetite changes seen with MT-II. Afamelanotide (the pharmaceutical name for MT-I, branded as Scenesse) received FDA approval in 2019 for erythropoietic protoporphyria. MT-II was never approved. MT-I is the cleaner but less potent option; MT-II produces stronger pigmentation at lower doses but with substantially more off-target effects.

Yes. MT-II primes melanocytes to produce melanin by activating the MC1R signaling cascade, but ultraviolet light is needed to trigger the full visible pigmentation response. Without UV exposure, users may see mild skin tone changes, but results will be slow and less noticeable. The commonly cited analogy is that MT-II loads the gun and UV pulls the trigger. For research protocols and community reports, 10-15 minutes of sun exposure several times per week during the loading phase is typically described as sufficient — far less than the hours required for natural tanning.

Most sources indicate that MT-II-induced tanning persists for 4-6 weeks after cessation without maintenance dosing. Some users report tans lasting several months after extended loading periods. The pigmentation lasts because melanin, once synthesized and deposited in keratinocytes, remains until those skin cells are naturally shed through epidermal turnover, which takes approximately 4-6 weeks. This is significantly longer than natural UV tanning, which typically fades within 1-2 weeks. Maintenance dosing of 500 mcg to 1 mg once or twice weekly can extend pigmentation indefinitely.

Yes. MT-II stimulates melanocytes broadly throughout the body, not just in areas exposed to sunlight. This means existing freckles darken, previously invisible freckles may become visible, and existing moles can change in color or size. New moles may also form. This is one of the most consistently reported cosmetic effects in community discussions and is documented in the medical literature (PMID: 28266027). Some freckle and mole changes reverse after stopping MT-II; others persist permanently. Baseline dermatological photography before starting is recommended to track any changes.

MT-II is not FDA-approved for any human use. It is not classified as a controlled substance in the United States, meaning possession is not a criminal offense. However, selling MT-II for human consumption violates FDA regulations — it is marketed online as a research chemical labeled for research purposes only. In Australia, it is Schedule 4 (prescription-only) and illegal to sell or advertise for tanning. In the UK and EU, it is unlicensed but widely available online. MT-II is expected to remain on the restricted peptide list under the anticipated 2026 FDA reclassification due to skin cancer and cardiovascular concerns.

Multiple double-blind, placebo-controlled studies demonstrated that MT-II initiates erections in men with both psychogenic and organic erectile dysfunction. In psychogenic ED, MT-II produced erections in 8 of 10 men with 38 minutes of adequate rigidity versus 3 minutes for placebo (PMID: 9679884). In organic ED, erections occurred in 63% of administrations versus 5% for placebo (PMID: 11018622). MT-II works through central MC4R activation in the brain, a different mechanism than PDE5 inhibitors like sildenafil. However, MT-II is not FDA-approved for erectile dysfunction. Its derivative PT-141 (bremelanotide) was approved as Vyleesi for female sexual dysfunction.

Animal studies using intracerebroventricular (direct brain) infusion show MT-II suppresses appetite and reduces body mass through MC3R and MC4R activation. Rat studies demonstrated approximately 30% food intake reduction, 80% adiposity reduction, and chronic body mass reduction that persisted even after appetite returned to normal (PMID: 20034526, 28051332). Critically, these studies used direct brain infusion, not subcutaneous injection as used in humans — the route difference significantly limits translation. No controlled human weight-loss studies have been conducted. Human data is limited to incidental appetite suppression reported as a side effect in tanning and erectile dysfunction trials.

Clinical research used subcutaneous doses of 0.025 mg/kg body weight, approximately 1.5-2.0 mg for a 70-80 kg adult (PMID: 8637402, 9679884). Community-reported protocols typically use a two-phase approach: a loading phase of 250-500 mcg daily for 1-4 weeks combined with brief UV exposure, followed by maintenance dosing of 500 mcg to 1 mg once or twice weekly. Starting at 100-250 mcg to assess nausea tolerance is widely recommended. MT-II is not FDA-approved and no standardized dosing exists. All dosing information is educational only.

Subcutaneous injection is significantly more effective. Nasal spray formulations are approximately 40-50% less bioavailable because the nasal mucosa is designed to filter foreign substances. This means roughly double the dose is needed via nasal spray to approach the effects of subcutaneous injection. Injection provides faster onset and more predictable absorption. Nasal spray advantages include convenience, no needle required, and painless administration. Pharmacokinetic studies of the melanocortin analog class confirmed zero oral bioavailability, making injection or nasal the only viable routes (PMID: 9113347).

No. Despite being one of the most frequently asked questions in peptide communities, users with extended MT-II use consistently report no eye color change. The melanocortin receptors present in the iris do not appear to be significantly activated by systemic MT-II use at the doses typically employed. Iris pigmentation is determined primarily during early development and is structurally distinct from the melanin production pathway MT-II activates in skin melanocytes.

Yes. A documented case report described a 39-year-old male who developed rhabdomyolysis (severe muscle breakdown with CPK peaking at 17,773 IU/L) and renal dysfunction after injecting 6 mg of MT-II — approximately six times the typical starting dose — purchased from an online source (PMID: 23121206). He required 3 days of ICU care. A separate case report documented renal infarction attributed to MT-II use (PMID: 31953620). These serious adverse events appear to be associated with excessive dosing and unregulated product quality. There are no long-term safety studies for MT-II.

Afamelanotide is a linear alpha-MSH analog originally designated Melanotan I (MT-I). Unlike the cyclic MT-II, afamelanotide selectively targets MC1R only, producing skin pigmentation without the sexual, appetite, and cardiovascular side effects of MT-II. It was FDA-approved in October 2019 as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme sun sensitivity. The landmark NEJM trial showed afamelanotide increased pain-free sun exposure and reduced phototoxic reactions (PMID: 26132941). Afamelanotide and MT-II share the same melanocortin pathway origin but differ significantly in selectivity, safety profile, and regulatory status.

Yes. Fair-skinned individuals (Fitzpatrick types I-II) often see the most dramatic visual results because there is more room for visible pigmentation change. However, fair-skinned users also report the highest rates of freckle darkening, uneven pigmentation patches (particularly on the face), and nausea. They may require a longer loading phase to achieve desired results. Fair-skinned individuals are also in the highest risk category for melanoma and mole-related concerns. Extra caution with mole monitoring and lower starting doses are particularly important for this group.

No. There are zero published long-term safety studies on MT-II in humans. The TGA (Australia), FDA, HPRA (Ireland), and multiple other health authorities have explicitly noted this gap. Pharmaceutical development was halted around 2003 due to safety concerns, and no company has pursued full clinical trials since. All current use is unregulated and unmonitored. Long-term safety data exists only for the MT-I derivative afamelanotide, which showed acceptable safety over 8 years of use in EPP patients (PMID: 25494545). However, afamelanotide's selective MC1R profile is substantially different from MT-II's non-selective receptor activation.